Your browser doesn't support javascript.
loading
Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies.
Cifaldi, Cristina; Brigida, Immacolata; Barzaghi, Federica; Zoccolillo, Matteo; Ferradini, Valentina; Petricone, Davide; Cicalese, Maria Pia; Lazarevic, Dejan; Cittaro, Davide; Omrani, Maryam; Attardi, Enrico; Conti, Francesca; Scarselli, Alessia; Chiriaco, Maria; Di Cesare, Silvia; Licciardi, Francesco; Davide, Montin; Ferrua, Francesca; Canessa, Clementina; Pignata, Claudio; Giliani, Silvia; Ferrari, Simona; Fousteri, Georgia; Barera, Graziano; Merli, Pietro; Palma, Paolo; Cesaro, Simone; Gattorno, Marco; Trizzino, Antonio; Moschese, Viviana; Chini, Loredana; Villa, Anna; Azzari, Chiara; Finocchi, Andrea; Locatelli, Franco; Rossi, Paolo; Sangiuolo, Federica; Aiuti, Alessandro; Cancrini, Caterina; Di Matteo, Gigliola.
Afiliação
  • Cifaldi C; Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Brigida I; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Barzaghi F; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Zoccolillo M; Pediatric Immunohematology and Bone Marrow Transplantation Unit, Scientific Institute for Research and Healthcare (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
  • Ferradini V; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Petricone D; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cicalese MP; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Lazarevic D; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Cittaro D; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Omrani M; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Attardi E; Pediatric Immunohematology and Bone Marrow Transplantation Unit, Scientific Institute for Research and Healthcare (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
  • Conti F; Vita Salute San Raffaele University, Milan, Italy.
  • Scarselli A; Center for Translational Genomics and BioInformatics, San Raffaele Scientific Institute, Milan, Italy.
  • Chiriaco M; Center for Translational Genomics and BioInformatics, San Raffaele Scientific Institute, Milan, Italy.
  • Di Cesare S; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Licciardi F; Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Davide M; Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Ferrua F; Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Canessa C; Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Pignata C; Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Giliani S; Division of Immunology and Rheumatology, Department of Paediatric Infectious Diseases, Regina Margherita Children's Hospital, University of Turin, Turin, Italy.
  • Ferrari S; Division of Immunology and Rheumatology, Department of Paediatric Infectious Diseases, Regina Margherita Children's Hospital, University of Turin, Turin, Italy.
  • Fousteri G; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Barera G; Pediatric Immunohematology and Bone Marrow Transplantation Unit, Scientific Institute for Research and Healthcare (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
  • Merli P; Vita Salute San Raffaele University, Milan, Italy.
  • Palma P; Pediatric Immunology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Cesaro S; Meyer Children's Hospital, Florence, Italy.
  • Gattorno M; Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
  • Trizzino A; Department of Molecular and Translational Medicine, A. Nocivelli Institute for Molecular Medicine, University of Brescia, Brescia, Italy.
  • Moschese V; Unit of Medical Genetics, St. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy.
  • Chini L; Division of Immunology Transplantation and Infectious Diseases (DITID), Diabetes Research Institute (DRI) IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Villa A; Pediatric Department, San Raffaele Scientific Institute, Milan, Italy.
  • Azzari C; Department of Onco-Hematology and Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Finocchi A; Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, Rome, Italy.
  • Locatelli F; Paediatric Hematology-Oncology, "Ospedale della Donna e del Bambino", Verona, Italy.
  • Rossi P; Pediatric and Rheumatology Unit, Giannina Gaslini Institute, Genoa, Italy.
  • Sangiuolo F; Department of Pediatric Hematology and Oncology, "ARNAS Civico Di Cristina Benfratelli" Hospital, Palermo, Italy.
  • Aiuti A; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Cancrini C; Pediatric Immunopathology and Allergology Unit, University of Rome Tor Vergata Policlinico Tor Vergata, Rome, Italy.
  • Di Matteo G; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Front Immunol ; 10: 316, 2019.
Article em En | MEDLINE | ID: mdl-31031743
Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders. Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes. Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology. Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrent method was highly successful for those cases with well-defined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage. Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças da Imunodeficiência Primária Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças da Imunodeficiência Primária Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article